| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4075 | Pergolide Mesylate | Agonist of dopamine receptor subtypes D1 and D2 |
|
| DCC4076 | Peridinin | Exceptionally Potent and Membrane-Embedded Inhibitor of Bilayer Lipid Peroxidation |
|
| DCC4077 | Perindopril | Non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor |
|
| DCC4078 | Pet-16 | Novel allosteric inhibitor of E. coli Hsp70 (DnaK) and human Hsp70 proteins |
|
| DCC4079 | Pex14-pex5 Inhibitor-5 | First Inhibitor of PEX14-PEX5 Protein-Protein Interaction (PPI) with Trypanocidal Activity |
|
| DCC4080 | Pf-03084014 | Novel γ-secretase inhibitor |
|
| DCC4081 | Pf-03671148 | Dose dependent inhibitor of multiple fibrotic genes |
|
| DCC4082 | Pf-04363467 Hydrochloride | Selective dopamine D3/D2 receptor antagonist |
|
| DCC4083 | Pf-04671536 Hydrochloride | Novel potent and selective PDE8B/8A inhibitor |
|
| DCC4084 | pf-04859989 | Irriversible inhibitor of kynurenine amino transferase II (KAT II) |
|
| DCC4085 | Pf-05109794 | Novel selective hTRPV4 Antagonist (hTRPV4 IC50 49nM; rTRPV4 IC50 1,150nM) |
|
| DCC4086 | Pf-05214030 | Novel potent TRPV4 antagonist (hTRPV4 IC50 4nM; rTRPV4 IC50 27nM) |
|
| DCC4087 | Pf-06371900 | Novel potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor |
|
| DCC4088 | Pf-06424439 Mesylate Featured | Potent and selective inhibitor of diacylglycerol acyltransferase 2 (DGAT2) |
|
| DCC4089 | Pf-06655075 | Novel non-brain-penetrant long-acting peptide oxytocin (OT) receptor agonist with increased selectivity for the OT receptor and significantly increased pharmacokinetic stability |
|
| DCC4090 | Pf-06745013 | Novel potent and selective inhibitor of MAP4K4 |
|
| DCC4091 | Pf-06756394 | Novel tyrosine residues probe, rationally targeting active site |
|
| DCC4092 | Pf-06758955 Hydrochloride | Novel potent and selective inhibitor of MAP4K4 |
|
| DC30002 | PF-06835919 Featured | PF-06835919, also known as MDK1846, is a potent ketohexokinase (KHK) inhibitor. PF-06835919 is reported in patent US 20170183328 A1, example 4. Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to further elucidate the effect of KHK inhibition on these metabolic disorders. |
|
| DCC4094 | Pf-06843195 Prodrug | Novel prdrug of PF-06843195, a potent PI3Kα-selective inhibitor |
|
| DCC4095 | Pf-06939999 | Novel SAM Competitive PRMT5 Inhibitor, Demonstrating Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance |
|
| DCC4096 | Pf1070a | Natural cyclic tetrapeptide HDAC Inhibitor through the inhibition of PfHDAC1 catalytic activity, potently inducing the synthesis of metallothionein |
|
| DCC4097 | Pf-184563 | Potent, selective non-peptidic antagonist of the V1a receptor |
|
| DCC4098 | Pf-3604861 | Novel dual H3/4 histamine receptor antagonist |
|
| DCC4099 | Pf-3837 | Highly selective, extremely potent Mps1 kinase inhibitor |
|
| DCC4100 | Pf-4522654 | Potent and selective 5-HT2C receptor agonist |
|
| DCC4101 | Pf-5177624 | Selective and potent PDK1 inhibitor inducing anti-tumor activity in breast cancer cells |
|
| DCC4102 | Pf-543 Hydrochloride Featured | Novel, potent and specific inhibitor of sphingosine kinase-1 (SphK1) |
|
| DCC4103 | pf-5466 | Antimalarial, actively against Plasmodium liver stages |
|
| DCC4104 | Pf-562271 Tosylate | Potent, ATP-competitive, reversible inhibitor of FAK |
|
